N-cadherin has recently emerged as a potential therapeutic target for three types of brain cancers: meningioma (Magill et al., 2020), neuroblastoma (Lammens et al., 2012) and glioblastoma multiforme (Smits et al., 2020). The gene discussed is CDH2; the disease is neuroblastoma.